Deeper inhibition of the mitogen-activated protein kinase (MAPK) pathway by targeting both MEK and BRAF may help improve progression-free survival (PFS) outcomes in patients with advanced BRAF V600–mutated melanoma, according to a retrospective analysis. “Therapeutic targeting of the constitutively active MAPK signaling pathway in patients with advanced melanomas harboring the BRAF V600 mutation has demonstrated meaningful clinical benefit,” wrote